Core Viewpoint - The CSI Hong Kong-Shanghai-Macau Pharmaceutical R&D Service Index has shown a decline of 20.89% over the past month, while it has increased by 1.05% over the last three months and decreased by 2.89% year-to-date [1] Group 1: Index Performance - The CSI Hong Kong-Shanghai-Macau Pharmaceutical R&D Service Index is currently at 1344.91 points [1] - The index was established on December 29, 2017, with a base point of 1000.0 [1] Group 2: Index Composition - The top ten weighted companies in the index are: WuXi Biologics (18.47%), WuXi AppTec (13.28%), Hangzhou Tigermed Consulting (7.0%), and others [1] - The index consists of no more than 50 listed companies providing drug research, development, and production services [1] Group 3: Market Distribution - The market distribution of the index holdings is as follows: Shenzhen Stock Exchange (35.66%), Shanghai Stock Exchange (32.49%), and Hong Kong Stock Exchange (31.85%) [1] Group 4: Industry Breakdown - The industry composition of the index holdings includes: Pharmaceutical and Biotechnology Services (86.14%), Chemical Drugs (11.95%), Agricultural Chemicals (1.39%), and Biopharmaceuticals (0.52%) [2] Group 5: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Special circumstances may lead to temporary adjustments of the index [2]

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the Hong Kong healthcare sector, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark [1][19][25]. Core Insights - The report highlights President Trump's executive order aimed at lowering prescription drug prices through various measures, including optimizing federal healthcare programs and enhancing regulatory transparency [4][6]. - Key aspects of the executive order include standardizing negotiation timelines for drug prices, promoting competition through accelerated approvals for generics and biosimilars, and increasing transparency in pharmacy benefit manager (PBM) fees [7][4]. Summary by Sections Investment Focus - Companies rated "Outperform" include JD Health, WuXi Biologics, Alibaba Health, and many others, reflecting a positive outlook for the healthcare sector in Hong Kong [1]. Policy Developments - The executive order includes provisions for negotiating drug prices after a uniform timeline of 13 years for both small-molecule and large-molecule drugs, which aims to balance innovation incentives [4][7]. - The order also emphasizes the need for Congressional cooperation for full implementation, suggesting a prolonged timeline for these changes [6]. Market Trends - The report notes the importance of monitoring the evolution of U.S. tariff policies and domestic demand as they relate to the pharmaceutical industry [3]. - It also discusses the recovery of domestic consumption demand policies, which could positively impact the healthcare sector [3].

Investment Rating - The industry investment rating is "Outperform the Market" [1][50]. Core Insights - Eli Lilly's first oral small molecule GLP-1 drug, Orforglipron, has successfully completed Phase 3 clinical trials, which is expected to change the landscape of weight loss medications [3][4]. - The ACHIEVE-1 trial showed that Orforglipron significantly reduced HbA1c levels by 1.3% to 1.6% from a baseline of 8.0% after 40 weeks, with over 65% of patients achieving HbA1c levels ≤6.5% [3][4]. - Patients receiving the highest dose of Orforglipron lost an average of 7.3 kg, indicating potential for further weight loss [4]. - Eli Lilly plans to submit a global application for Orforglipron for weight management by the end of this year and for type 2 diabetes treatment in 2026 [4][5]. Summary by Sections Industry Overview - The successful Phase 3 trial of Orforglipron positions it as a potential second oral GLP-1 drug in the U.S., following Novo Nordisk's Rybelsus [5]. Investment Strategy - Focus on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [7]. - Recommended companies include innovative drug developers and those with strong overseas market potential [7]. Key Companies to Watch - **Nocera Health**: Expected to achieve over 1 billion yuan in revenue from its core product, with a projected 49% year-on-year growth [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [11]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [13]. - **Aier Eye Hospital**: Benefiting from increasing demand in ophthalmology and ongoing overseas expansion [22]. Market Performance - The pharmaceutical sector saw a decline of 0.36% last week, while the broader market index rose by 0.59% [25][36].

Group 1 - The core index of the CSI Hong Kong Stock Connect Medical Theme Index has shown a decline of 11.89% over the past month, an increase of 13.46% over the past three months, and a year-to-date increase of 8.75% [1] - The index consists of 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [1] - The index is based on a starting point of 1000.0 points as of December 31, 2018 [1] Group 2 - The top ten weighted companies in the index include WuXi Biologics (15.72%), JD Health (11.24%), Alibaba Health (7.31%), Sinopharm (5.92%), WuXi AppTec (5.0%), Kingstar BioTech (3.88%), Weigao Group (3.72%), CanSino Biologics (2.43%), MicroPort Medical (2.4%), and Innovent Biologics (2.35%) [1] - The index is exclusively composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - The industry composition of the index includes 35.98% in medical services, 30.61% in pharmaceuticals and biotechnology, 12.17% in medical devices, 10.73% in chemical drugs, 10.09% in biological drugs, and 0.42% in traditional Chinese medicine [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers and acquisitions [2]

Group 1 - The core index of the CSI Hong Kong Stock Connect Biotechnology Theme Index closed at 1134.61 points, with a decline of 3.59% over the past month, an increase of 24.05% over the past three months, and a year-to-date increase of 20.15% [1] - The index consists of 50 listed companies involved in biopharmaceuticals, pharmaceuticals, and biotechnology services, reflecting the overall performance of biotechnology theme companies within the Hong Kong Stock Connect [1] - The index was established on December 28, 2018, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: BeiGene (15.69%), WuXi Biologics (11.81%), Innovent Biologics (10.68%), CanSino Biologics (8.36%), CSPC Pharmaceutical Group (6.36%), China Biologic Products (5.81%), Hansoh Pharmaceutical (3.68%), Zai Lab (3.48%), 3SBio (3.22%), and WuXi AppTec (2.82%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - In terms of industry composition, biopharmaceuticals account for 52.00%, chemical drugs for 25.67%, pharmaceutical and biotechnology services for 19.19%, and medical devices for 3.14% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year, with a sample adjustment ratio generally not exceeding 20% [2] - Special adjustments may occur under certain circumstances, such as delisting or significant corporate actions like mergers or acquisitions [2]

截至2025年4月18日 10:56，港股医药ETF(159718)上涨0.30%，最新价报0.67元。拉长时间看，截至2025年4月17日，港股医药ETF近1周累计上涨4.19%，涨 幅排名可比基金1/4。 流动性方面，港股医药ETF盘中换手4.75%，成交1032.30万元。拉长时间看，截至4月17日，港股医药ETF近1周日均成交8710.12万元。 规模方面，港股医药ETF本月以来规模增长1569.02万元，实现显著增长，新增规模位居可比基金1/4。 份额方面，港股医药ETF近2周份额增长5200.00万份，实现显著增长，新增份额位居可比基金1/4。 资金流入方面，港股医药ETF最新资金净流出134.67万元。拉长时间看，近9个交易日内有5日资金净流入，合计"吸金"3300.54万元，日均净流入达366.73万 元。 截至2025年4月18日 10:55，中证医药及医疗器械创新指数(931484)下跌0.49%。成分股方面涨跌互现，华东医药(000963)领涨5.19%，惠泰医疗(688617)上涨 1.43%，艾力斯(688578)上涨0.83%；海思科(002653)领跌5.15%，安图生物(603 ...

港股医药股持续走弱，歌礼制药(01672.HK)跌超12%，药明生物(02269.HK)跌超5%，再鼎医药 (09688.HK)、昭衍新药(06127.HK)等跟跌。 ...

Group 1: Report Core View - The report focuses on the allocation value of Hong Kong stocks, the types of hybrid bond funds allocating Hong Kong stocks, a case study of fund managers with significant exposure to Hong Kong - enhanced hybrid bond funds, and concludes with investment suggestions [1][3][66] Group 2: Allocation Value of Hong Kong Stocks Sub - group 1: Positive Factors for Hong Kong Stocks - Southbound capital has been flowing into Hong Kong stocks, and the expectation of the Fed's interest rate cut is favorable for Hong Kong stocks [7][8][10] - Hong Kong stocks have high - quality and scarce underlying assets, including leading Internet companies, innovative biopharmaceutical enterprises, emerging consumer sectors, and high - dividend assets [16][17][23] - The cost - effectiveness of Hong Kong stocks has increased, and the proportion of Hong Kong stocks in hybrid bond funds has significantly risen [24][25][29] Sub - group 2: Screening of Hybrid Bond Funds Allocating Hong Kong Stocks - The screening criteria for Hong Kong - enhanced hybrid bond funds are hybrid bond funds with an average Hong Kong stock - to - equity ratio of over 20% in the past eight quarters and a consistent equity position of over 5% [30] - The Hong Kong - enhanced hybrid bond funds have shown good performance in the past two years, with average annualized returns in each equity position range exceeding 3% [32][33] - Most Hong Kong - enhanced hybrid bond funds have a large - cap or ultra - large - cap style, with a balanced or value style, and generally low exposure to growth [34][35][39] - Most fund managers have allocated Hong Kong - enhanced hybrid bond funds, with GF Fund, Huatai - PineBridge Fund, Fullgoal Fund, and Anxin Fund having larger management scales and more products [42][43][50] Sub - group 3: Case Study of GF Fund's Hong Kong - enhanced Hybrid Bond Funds - GF Fund's Hong Kong - enhanced hybrid bond funds have generally achieved positive returns in the past two years, with most annualized returns exceeding 3% [54] - The Hong Kong stock position of GF Fund's Hong Kong - enhanced hybrid bond funds is divided into stable and phased allocation types, with a central average Hong Kong stock - to - equity ratio of about 32% [51][57][58] - GF Fund's Hong Kong - enhanced hybrid bond funds show diverse styles, including balanced allocation, "core + satellite" configuration, and "dividend + Internet" dumbbell - shaped configuration [59][60][61] - The Hong Kong stock positions of GF Fund's Hong Kong - enhanced hybrid bond funds have contributed positive returns in the past two years, with some funds showing significant contributions [63][64] Group 3: Conclusion - Hong Kong - enhanced hybrid bond funds can be divided into stable and phased allocation types, suitable for investors with different investment preferences [66] - Most Hong Kong - enhanced hybrid bond funds have a large - cap or ultra - large - cap style, with a balanced or value style and low exposure to growth [66] - Dividend and Internet are the most popular sectors in Hong Kong stock positions, and balanced allocation is the most common strategy [66]

图名先生第三位是SVP以及Head of IR,Lina,Lina Fan女士然后以及整个药物生物的IR团队那么without further delay那我把这个时间交给公司非常感谢谢谢John非常高兴给大家机会跟大家来分享我们2024年的业绩我们总体来说对2024年非常满意而且2025年是加速增长 如果熟悉我们的投资人,我非常喜欢用这一个slide来总结我们2024年的业绩。左边是我们的业务的数据,右边更多的是financial的数据。 如果看项目数,我们过去一年项目数增长17%,在这么大的一个Portfolio,近700个项目,现在增加到817个项目,相当的了不起,尤其是去年,大家也都知道,噪音还是非常大的,就是生物技术的投融资不一定那么稳健,还有别的噪音也非常大。 即使这样的情况下我们最终我们是非新冠业务的增速我们达到了13%我们管理层对这个非常满意我觉得对我们最开心的还是说我这边已经切过了你们在第几页我在第五页我们看到还是第一页样目比较我这边看到第五页怎么那么奇怪呢 好了现在第五页对现在回到第五页是吗所有人都在第五页吗对对对我这边看到第五页的OK好对我觉得去年2024年我觉得在这个大环境非常复杂的情 ...

以下文章来源于创业邦 ，作者刘杨楠 作 者 | 刘杨楠 来源 | 创业邦 导 语 ：映恩生物创始人 朱忠远与"药明系"有诸多渊源 。 2025年4月15日，映恩生物(Endure Biologics)在港股上市。映恩生物IPO发行价定为每股94.6港元， 每股开盘价为181港元，涨幅逾91%。 映恩生物无疑是近两年来港股18A规则（2018年4月，港交所推出新的《主板上市规则》，新增第 18A章，允许未盈利、无收入的生物科技公司上市。以下此类企业简称"18A"）下的现象级企业。 创业邦 . 创业邦，国际创新生态服务平台。我们致力于打造全球化的创业生态，深度服务创新经济及其推动者， 并为创业者提供一站式解决方案。 映恩生物此次IPO募资额达15.55亿港元，创下港股18A生物科技板块的IPO规模纪录；同时引入15 名基石投资者，共计认购6500万美元（约5.05亿港元），国际配售14.9倍超额认购。此次IPO后，映 恩生物投后估值将达11亿美元，较IPO前最后一轮融资估值增幅达到307%。 但对成立不到6年的映恩生物来说，上市只是一个开始。 "药明系"捧出港股18A最大IPO 映恩生物能够快速崛起，掌舵人朱忠远 ...